A resting pulse is a readout, not a rate to force
This is a reading, not a dial. Resting pulse reflects an aerobic base built elsewhere — no trial in this set has shown that lowering it lowers all-cause mortality.
A sitting pulse, not a rate-lowering prescription. Zhang’s 1.09 per 10 bpm is a relative risk. The knots, the 70 = 1.0 zero, and the steepening above 80 are constructed.
Time
One sitting reading, fully at rest
- Level
- Any
- Impact
- Low (the measurement)
- Equipment
- None — or a validated pulse device
Dose
70 bpm = HR 1.0. 60 bpm prints 0.90. 40–50 floor 0.85. Above 80 the curve steepens past Zhang’s linear slope (1.25 at 90 vs ~1.19). Near 60–80 it tracks Zhang 2016 general-population ACM RR 1.09 (1.07–1.12) per 10 bpm — RR, not HR. PCHIP interiors are constructed.
The 70 = 1.0 zero, the 40–50 floor, and the steepening above 80 bpm are constructed — PCHIP interiors, not read off Zhang, Aune, or Raisi-Estabragh.
Dose-response shape: monotone
How to get there
The Zone 2 protocol on this site is the on-ramp for this readout. In trials in healthy people, regular exercise, especially endurance training and yoga, lowered resting heart rate (Reimers 2018); those trials do not show that lowering the number changes deaths.
Seated pulse, same time of day, same conditions.
A low pulse from illness, overreaching, or a rate-limiting drug is not the same finding as a low pulse from fitness — do not chase the number itself. SIGNIFY (Fox et al. 2014) lowered heart rate with a drug in heart patients and did not improve outcomes.
Evidence, by endpoint
| Endpoint | Grade | Citation |
|---|---|---|
| All-cause mortality per 10 bpm, general population | B | Zhang et al. 2016, CMAJ Supporting source (page meta, not the knot table). General-population only; search to 1 Jan 2015. 46 studies. ACM: 1,246,203 people / 78,349 deaths. Multivariate RR 1.09 (1.07–1.12) per 10 bpm, I² 92.3%, n=35 — RR, not HR. Trim-and-fill 1.04 (1.02–1.06). Categorical vs lowest: 60–80 bpm RR 1.12; >80 bpm RR 1.45. ACM spline vs 45 bpm is linear (p nonlinearity = 0.1); 90 bpm is the CV-mortality threshold, not an ACM cliff. ECG subgroup 1.06 vs non-ECG 1.15 per 10 bpm. |
| All-cause mortality per 10 bpm, larger prospective mix | B | Aune et al. 2017, Nutrition, Metabolism and Cardiovascular Diseases Larger ACM meta (search to 29 Mar 2017). 87 studies overall; ACM n=48, RR 1.17 (1.14–1.19) per 10 bpm, I² 94.0%. Broader prospective mix than Zhang’s general-population-only pool. Webappendix high-vs-low ACM 1.69 (1.52–1.87). |
| All-cause mortality per 10 bpm, seated home-style pulse | B | Raisi-Estabragh et al. 2020, PLoS ONE UK Biobank n=502,534 (analysis 228,594 men / 272,737 women). Fully adjusted ACM per 10 bpm: men HR 1.22 (1.20–1.24), women 1.19 (1.16–1.22). Sitting Omron pulse, mean of two readings — closer to this slider than Zhang’s mixed ECG/non-ECG pool, and higher than Zhang’s 1.09. |
| All-cause mortality, ≥70 vs <70 bpm, off rate-lowering drugs | B | Custodis et al. 2016, Clinical Research in Cardiology Heinz Nixdorf RECALL, n=4,091 without known CAD (3,348 free of rate-lowering meds), median 10.5 y, 398 deaths. Off meds, RHR ≥70 vs <70: ACM HR 1.68 (1.30–2.18); coronary events 1.20 (0.82–1.77), NS. Per 5 bpm ACM 1.13 (1.07–1.20); coronary 1.02 (0.94–1.11), NS. Independent risk marker for ACM but not for coronary events. |
| All-cause mortality, highest vs lowest RHR quartile, age 60+ | C | He et al. 2022, Public Health 67,028 Chinese adults aged 60 and older, 9,326 deaths. Highest vs lowest resting-heart-rate quartile ACM HR 1.25 (1.17–1.33). |
| All-cause mortality, highest quartile, middle-aged Japanese adults | C | Okamura et al. 2004, American Heart Journal 8,800 Japanese adults, 16.5 years. Middle-aged men (30–59) in the highest quartile RR 1.45 (1.06–2.00); middle-aged women RR 1.94 (1.26–3.01). Not evident in adults 60 and older. |
| Cardiovascular death or nonfatal heart attack from lowering heart rate with a drug to a 55–60 bpm target, stable coronary disease | A | Fox et al. 2014, NEJM (SIGNIFY) Randomized trial, 19,102 heart patients with a resting rate of 70 or more. Ivabradine brought mean heart rate to about 61 versus 71 on placebo, with no significant difference in cardiovascular death or nonfatal heart attack (HR 1.08, 0.96–1.20), and more primary-endpoint events in patients with activity-limiting angina. Death from any cause, a secondary endpoint, also did not differ (HR 1.06, 0.94–1.21). Support for not chasing the number; a drug trial in heart patients, not the general population. |
| All-cause mortality from a randomized rate-lowering intervention, general population | X | Custodis et al. 2016: a marker for ACM, not a coronary-event predictor and not a rate-lowering trial. No trial in this set has shown that lowering resting pulse lowers all-cause mortality. The one rate-lowering trial here (SIGNIFY) was in heart patients, and its main endpoint was cardiovascular death or nonfatal heart attack. |
What the dose is
Seventy beats per minute is typical on this curve (HR 1.0). Sixty or under prints 0.90. Forty to fifty floors at 0.85. Those knots are constructed. Near 60–80 the slope is meant to sit next to Zhang et al. 2016 (CMAJ): general-population ACM RR 1.09 (1.07–1.12) per 10 bpm. Above 80 the curve steepens past that linear slope.
What the evidence shows
Zhang is a 46-study general-population meta (1,246,203 people / 78,349 deaths), grade B, RR not HR. Aune et al. 2017 is the larger ACM pool, RR 1.17 per 10 bpm across 48 studies. Raisi-Estabragh et al. 2020 is one UK Biobank cohort on a sitting Omron — closer to a home reading — at 1.22 / 1.19. Custodis et al. 2016 is the honesty paper: ≥70 vs <70 ACM HR 1.68 off rate-lowering drugs, coronary events not significant.
What the number is not
It is not a demonstration that lowering a pulse lowers the risk of death. No trial in this set has shown that lowering resting pulse lowers all-cause mortality. The one rate-lowering trial here (SIGNIFY) was a drug trial in heart patients, and it did not improve outcomes; for the general population the intervention endpoint stays grade X. It is not Zhang’s 90 bpm CV threshold pasted onto all-cause death. It is not Aune’s 1.17 or Raisi’s 1.22 — the curve stays on the constructed PCHIP.
How the pulse is taken
Zhang mixed ECG and non-ECG (1.06 vs 1.15 per 10 bpm). Raisi used a seated Omron, mean of two readings. Custodis excluded people on rate-lowering medication for the 1.68 contrast. The slider is one resting number. He et al. 2022 (quartile 1.25 in Chinese adults 60+) and Okamura et al. 2004 (1.45 in middle-aged Japanese men, 1.94 in women, not evident at 60+) are other instruments, not this zero point.
What argues against this
Raisi-Estabragh et al. 2020 is the closer instrument (seated Omron, mean of two) and a steeper slope: ACM HR 1.22 men / 1.19 women per 10 bpm versus Zhang’s pooled RR 1.09. Aune et al. 2017 is the larger ACM pool at RR 1.17 (1.14–1.19) per 10 bpm. Both argue the curve’s near-baseline slope may understate risk, not overstate it. Zhang’s own trim-and-fill is 1.04. The 90 bpm knot (HR 1.25) is not Zhang’s ACM cliff — ACM versus 45 bpm is linear; 90 bpm is cardiovascular mortality. Okamura’s signal is in middle-aged adults (men RR 1.45, women RR 1.94), not in people 60 and older. In older adults the link may still hold. A retrospective cohort of 67,028 Chinese adults aged 60 and older found higher all-cause mortality in the highest resting-pulse quarter (80 bpm or more) than in the lowest (41–69 bpm): HR 1.25 (1.17–1.33). Okamura found no clear link at 60 and older. Association only, from one cohort in one country, and it does not show that lowering the pulse helps. No trial in this set has shown that lowering a pulse lowers the risk of death.
Gotchas
- Zhang is RR 1.09, not an HR. Trim-and-fill 1.04. The curve’s printed values above 70 are 1.10 at 80 and 1.25 at 90, not 9%.
- 90 bpm in Zhang is the CV-mortality threshold versus 45 bpm, not an all-cause cliff. ACM is linear (p nonlinearity = 0.1).
- ECG subgroup 1.06 vs non-ECG 1.15 per 10 bpm. A watch or finger pulse is the non-ECG side.
- Custodis predicts death, not coronary events. Same slices: ACM 1.68, coronary 1.20 NS.
- The 70 = 1.0 zero, the 40–50 floor, and the steepening above 80 are constructed.
Safety
- A resting pulse is a measurement. This page does not prescribe a beta-blocker or a training plan to force 60 bpm.
Educational content only — not medical advice, diagnosis, or treatment. Not a medical device; not FDA evaluated. Consult a qualified healthcare professional about your own health, and call emergency services for urgent symptoms. Full medical disclaimer →